2.11.1 Non-steroidal Anti-inflammatory Drugs 17 2.11.2 Painkillers 18 2.11.3 Glucocorticoids 18 2.12 Biologic Disease-Modifying Anti-rheumatic Drugs 18 2.12.1 Tumor Necrosis Factor Alpha Inhibitors 18 2.12.2 Interleukin Inhibitors 18 2.12.3 Other Biologics that Target B- and T-Cell Antigens 19 2.13 Disease Scoring Methods for Measuring Treatment Efficacy 19 2.13.1 Radiographic Progression 19 2.13.2 Clinical Disease Activity Index and Simplified Disease Activity Index 19 2.13.3 Disease Activity Score-28 19 2.13.4 American College of Rheumatology 20 2.13.5 Health Assessment Questionnaire 20
3 Marketed Products 21 3.1 Overview 21 3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs 21 3.2.1 Methotrexate-Based Products 21 3.2.2 Xeljanz ( tofacitinib ) – Pfizer 22 3.3 Biologic Disease-Modifying Anti-rheumatic Drugs 23 3.3.1 Remicade ( infliximab ) – Johnson and Johnson , Merck 23 3.3.2 Remsima – infliximab biosimilar 24 3.3.3 Humira ( adalimumab ) – Abbvie 24 3.3.4 Enbrel ( etanercept ) – Amgen , Pfizer and Takeda Pharmaceutical 26 3.3.5 Rituxan ( rituximab ) – Genentech ( Roche ), Biogen IDEC 27 3.3.6 Reditux ( Non-comparable Biologic of Rituxan ) 28
Follow Us :